

US EPA ARCHIVE DOCUMENT



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
WASHINGTON, D.C. 20460

9-30-86  
CASWELL FILE

SEP 30 1986

005528 OFFICE OF  
PESTICIDES AND TOXIC SUBSTANCES

MEMORANDUM

SUBJECT: EPA Reg. No. 10308-3. Pynamin Forte. Chronic/  
Oncogenicity Feeding Study in Rats. Allethrin  
Data Call-In.

Tox. Chem. No. 25  
Project No. 1617

TO: Arturo Castillo (PM #17)  
Registration Division (TS-767c)

FROM: Pamela M. Hurley, Toxicologist *Pamela M. Hurley*  
Section II, Toxicology Branch  
Hazard Evaluation Division (TS-769c)

THRU: Edwin R. Budd, Section Head  
Section II, Toxicology Branch  
Hazard Evaluation Division (TS-769c)

Record No. 170855

Action Requested and Background:

Sumitomo Chemical Company, Ltd. has submitted a chronic/oncogenicity study on Pynamin Forte in rats in response to a data call-in notice from the USEPA. The Toxicology Branch has been requested to review the submitted study.

Response:

The Toxicology Branch (TB) has determined that Pynamin Forte did not prove to be an oncogen under the conditions of the study. Chronic effects related to the administration of the chemical consisted mainly of decreases in body weight gain in males and females (HDT) and in females (mid-dose, LOEL), increases in liver weights in males and females (HDT) and in males (mid-dose, LOEL), the presence of histiocyte phagocytosing crystals in the livers of females (mid- and high doses) and possible increases in kidney weights in males at the high dose level.

*Budd*  
*9/30/86*  
*W. J. ...*  
*9/30/86*

2. Test Animals and/or Other Test System (if applicable):

Species and Strain (sexes): male and female F344/DuCrj rats  
 Age: 4 weeks (5 weeks at start of test)  
 Weight(s): 70-84 g (females), 72-103 g (males) - main study  
             70-85 g (females), 84-105 g (males) - satellite groups  
 Source(s): Charles River Japan, Inc.  
 Housing: 5 animals/cage

3. Procedure:

- a. Dietary Preparation (if applicable): Test compound mixed in pulverized diet (CE-2, Clea Japan Inc.), weight/weight for 30 minutes.

Frequency of preparation: Intervals < 4 weeks

Storage conditions: Not given

Stability Analyses: Maximal preparing interval set at 4 wks on basis of data obtained from sponsor (data not given)

Homogeneity Analyses: Samples collected from top, middle and bottom layers of diet at each concentration and analyzed (once)

Concentration Analyses: Pynamin content analyzed 1x/month for each level

- b. Basis For Selection of Dosage Levels: A 5-week subacute study was conducted with dietary levels of 10000, 5000, 2500, 1250, 625 and 0 ppm. The NOEL was 625 ppm and the LOEL was 1250 ppm based upon body weight gain, liver weights, swelling of liver cells and narrowing tendency of sinusoids. The highest dose level was set at 2000 ppm for the chronic study.

- c. Animal Assignment and Dose Levels:

Test Group	Dose Admin- istered (ppm)	Main Study 123 weeks		Interim Sac. 26 weeks		Interim Sac. 52 weeks		Interim Sac. 78 weeks	
		male	female	male	female	male	female	male	female
Contr.	0	50	50	10	10	10	10	10	10
1	125	50	50	10	10	10	10	10	10
2	500	50	50	10	10	10	10	10	10
3	2000	50	50	10	10	10	10	10	10

- d. Procedures for Studies Other Than Feeding and/or Additions, Changes in Feeding Study: N/A
- e. Clinical Observations and Mortality: All animals examined daily for mortality and general behavior. Palpations at time of body weight recordings.
- f. Body Weight Determinations: Every week during first 14 weeks, biweekly thereafter.

- g. Food and/or Water Consumption: Two-day food consumption/cage weekly for first 14 weeks, biweekly thereafter. Food efficiencies calculated for all groups except satellite groups. Water intake measured at same intervals as food consumption.
- h. Ophthalmological Examinations (if applicable): Not done
- i. Clinical Pathology: (\*) recommended by Guidelines

1) Hematology:

Collection times for blood (including # of animals):  
Ten males and ten females/dose group killed at 26, 52 and 78 weeks and all survivors at 123 weeks. Animals fasted from day prior to sacrifice. Blood taken from abdominal aorta after laparotomy under ether anesthesia.

The following CHECKED (X) parameters were examined:

<input checked="" type="checkbox"/> <u>X</u> <input checked="" type="checkbox"/> Hematocrit (HCT)* <input checked="" type="checkbox"/> Hemoglobin (HGB)* <input checked="" type="checkbox"/> Leukocyte count (WBC)* <input checked="" type="checkbox"/> Erythrocyte count (RBC)* <input checked="" type="checkbox"/> Platelet count* <input checked="" type="checkbox"/> Total plasma protein (TP) <input checked="" type="checkbox"/> Leukocyte differential count*	<input checked="" type="checkbox"/> <u>X</u> <input checked="" type="checkbox"/> Mean corpustular HGB (MCH) <input checked="" type="checkbox"/> Mean corpustular HGB conc.(MCHC) <input checked="" type="checkbox"/> Mean corpustular volume (MCV) <input checked="" type="checkbox"/> Prothrombin times
---	--

2) Clinical Chemistry:

Collection times and animals same as those for hematology.

The following CHECKED (X) parameters were examined:

<input checked="" type="checkbox"/> <u>X</u> <u>Electrolytes:</u> <input checked="" type="checkbox"/> Calcium* <input checked="" type="checkbox"/> Chloride* <input checked="" type="checkbox"/> Magnesium* <input checked="" type="checkbox"/> Phosphorus* <input checked="" type="checkbox"/> Potassium* <input checked="" type="checkbox"/> Sodium* <u>Enzymes:</u> <input checked="" type="checkbox"/> Alkaline phosphatase <input checked="" type="checkbox"/> Cholinesterase <input checked="" type="checkbox"/> Creatinine phosphokinase* <input checked="" type="checkbox"/> Lactic acid dehydrogenase <input checked="" type="checkbox"/> Serum alanine aminotransferase (also SGPT)* <input checked="" type="checkbox"/> Serum aspartate aminotransferase (also SGOT)*	<input checked="" type="checkbox"/> <u>X</u> <u>Other:</u> <input checked="" type="checkbox"/> Albumin* <input checked="" type="checkbox"/> Blood creatinine* <input checked="" type="checkbox"/> Blood urea nitrogen* <input checked="" type="checkbox"/> Cholesterol* <input checked="" type="checkbox"/> Globulins <input checked="" type="checkbox"/> Glucose* <input checked="" type="checkbox"/> Total bilirubin* <input checked="" type="checkbox"/> Total protein* <input checked="" type="checkbox"/> Triglycerides <input checked="" type="checkbox"/> Uric acid <input checked="" type="checkbox"/> A/G ratio
--	--

CHECKED (X) tissues were preserved for histopathological examination and (XX) tissues were weighed upon removal from the animal. The (\*) tissues were recommended by the Guidelines.

<u>X</u>		<u>X</u>		<u>X</u>	
	Digestive system		Cardiovasc./Hemat.		Neurologic
x	Tongue	x	Aorta*	xx	Brain*
xx	Salivary glands*	xx	Heart*	x	Periph. nerve*
x	Esophagus*	x	Bone marrow*	x	Spinal cord (3 levels)*
x	Stomach*	x	Lymph nodes*	xx	Pituitary*
x	Duodenum*	xx	Spleen*		Eyes (optic n.)*
x	Jejunum*	xx	Thymus*		Glandular
x	Ileum*		Urogenital	xx	Adrenals*
x	Cecum*	xx	Kidneys*	x	Lacrimal gland
x	Colon*	x	Urinary bladder*	x	Mammary gland*
x	Rectum*	xx	Testes*	x	Parathyroids*
xx	Liver*		Epididymides	xx	Thyroids*
	Gall bladder*	x	Prostate		Other
x	Pancreas*	x	Seminal vesicle	x	Bone*
	Respiratory	xx	Ovaries	x	Skeletal muscle*
x	Trachea*	x	Uterus*	x	Skin and subcutaneous tissue
xx	Lung*	x	Vagina	x	All gross lesions and masses
x	Nasal cavity			x	Ear + Zymbal's gland
x	Larynx			x	Eyeballs
				x	Harder's gland

1. Statistical Analyses: Significance of differences between control and treated groups were determined by Student's t test for means; and by Fisher's exact test for frequency. Differences considered significant at levels of 1% ( $p < 0.01$ ) and 5% ( $p < 0.05$ ).

## B. RESULTS:

1. Dietary Preparation: Homogeneity - The analysis revealed that the amount of Pynamin Forte in the feed sample ranged from 89-100% of the expected value at the 125 ppm level, from 86-96% of the expected value at the 500 ppm level and from 87-97% of the expected value at the 2000 ppm level. Concentration Analyses - The content of Pynamin Forte was consistently lower than the desired values. For the lowest dose level, the mean amount of the test chemical was 87.6% of the expected value, for the mid-dose level it was 86.3% of the expected value and for the high dose it was 88% of the expected value. These values, however, were not so low that it was considered necessary to alter the conclusions reached concerning the NOEL's and LOEL's for the chemical. The mean intake of the test compound in mg/kg/day

6. Hematology: Statistically significant observations for specific hemato-logical parameters were scattered throughout the treated groups at all of the scheduled sacrifice times. None of these findings were biologically significant, however, because there were no dose-related trends and there was no consistency in the observations within successive scheduled sacrifices.
7. Clinical Chemistry: In males, statistically significant decreases in GOT, GPT and alkaline phosphatase were observed at the highest dose level at 26 and 52 weeks (decreased GPT was also noted at the mid-dose level at 26 weeks). GPT was significantly increased at the terminal sacrifice in high dose males. There were other statistically significant observations as well, however, none of these appear to be biologically significant because there were no dose-related trends and because there was no consistency in the observations within successive scheduled sacrifices.
8. Urinalysis: At 26 weeks, males in all groups had a slight increase in pH, and in protein and crystalline components of urinary sediments. At 52 weeks, males in the mid- and high dose levels again exhibited a slight increase in protein. At week 78, findings in treated and control animals were similar. At week 123 (termination), all treated male groups and the 500 ppm group of the females exhibited greater urinary specific gravity. Other findings in all the treated groups at all the scheduled sacrifice times appeared to be similar to controls.
9. Gross Pathology: In general, gross observations were similar in all treated groups when compared to controls. This was true for animals examined at scheduled sacrifices as well as for those necropsied which either died or were sacrificed in extremis during the course of the study. Sporadic findings in the older animals included swelling of various organs and tissues, granular surfaced livers and kidneys, discoloration of various organs, atrophy of the testes, cyst formation of the ovaries, tumors on the skin and subcutaneous tissues, alopecia and turbidity in the eyes.
10. Organ Weights: The liver was the one organ which consistently had a higher absolute and relative weight in treated animals, both male and female when compared to controls. The following tables summarize the mean absolute and relative liver weight data for all the sacrifice times, including those animals which died or were sacrificed in extremis and whose organs were not severely autolyzed.

The significant increase in liver weights at the lowest dose level in males was not supported by any other biological parameters, was not different from historical control values in the same strain of rat from the same laboratory, and therefore was not considered to be biologically significant. Thus, the data indicates that there were significant increases in liver weights in males at the mid and high dose levels and in females at the high dose level. The kidney in the high dose male animals was the only other organ weight which may have significantly increased over control animals. At 78 weeks the mean absolute kidney weights were significantly increased in the high dose males ( $p=0.01$ ), and at 52, 78 and 123 weeks (terminal sacrifice) the mean relative kidney weights were also significantly increased in high dose males over the controls ( $p=0.01$ ,  $0.01$  and  $0.05$ , respectively). Changes in weights of other organs were not consistent and thus were not biologically significant.

#### 11. Histopathology:

- a. Nonneoplastic lesions: The presence of histiocyte infiltration in association with separation of crystals in the livers of females of the 2000 ppm and 500 ppm groups was consistently observed at all sacrifice times (see the following table). This effect was also observed in 2 males which died during the study (2000 ppm group).

#### Histiocyte Phagocytosing Crystals in the Liver

Time of Sacrifice	Females				Males			
	0ppm	125ppm	500ppm	2000ppm	0ppm	125ppm	500ppm	2000ppm
26 Weeks	0/10 <sup>a</sup>	0/10	2/10	5/10	0/10	0/10	0/10	0/10
52 Weeks	0/10	0/10	7/10	10/10	0/10	0/10	0/10	0/10
78 Weeks	0/10	0/10	10/10	10/10	0/10	0/10	0/10	0/10
Term. - 123 Weeks	0/23	0/23	14/28*	31/35*	0/23	0/19	0/13	0/24
Animals which died during study	0/27	0/27	14/22*	14/15*	0/27	0/31	0/37	2/26

a Number of Observations per Number Examined. \*Significant ( $p<0.01$ )

No other nonneoplastic lesions were considered to be attributable to the test material. The following table summarizes the incidences of nonneoplastic lesions for selected tissues.

Summary of Nonneoplastic Lesions from Selected Rat Tissues  
 Pyramin Forte Rat Chronic Feeding Study (Continued)

Organ and Findings	Female				Male			
	Oppm	125ppm	500ppm	2000ppm	Oppm	125ppm	500ppm	2000ppm
Pancreas	(50)	(50)	(50)	(49)	(50)	(49)	(50)	(50)
Normal	31	25	40	34	27	24	26	26
Atrophy of acinar cells	12	17	8	12	12	15	15	18
Islet-cell hyperplasia	0	0	1	0	2	4	3	1
Liver	(50)	(50)	(50)	(50)	(50)	(50)	(50)	(50)
Normal	20	12	12	1	5	4	1	3
Lymphocytic accumulations	3	0	4	8	3	4	1	0
Fatty metamorphosis	5	14	7	9	3	8	8	7
Granuloma	4	1	10	4	0	1	0	0
Necrosis	2	1	4	1	3	8	2	4
Histiocytes phagocytosing crystals	0	0	28**	45**	0	0	0	2
Bile duct proliferation	2	8	8	7	32	35	43	36
Kidney	(50)	(50)	(50)	(50)	(50)	(50)	(50)	(50)
Normal	5	3	7	2	0	5	6	3
Calcification	38	36	34	45	1	0	0	0
Chronic nephropathy	8	8	13	17	40	36	33	40
Proteinaceous cast	11	11	6	8	10	7	10	4
Testis	(50)	(50)	(50)	(50)	(50)	(50)	(50)	(50)
Normal	0	1	0	0	0	1	0	0
Atrophy	2	4	2	2	2	4	11	1
Interstitial cell hyperplasia	2	0	0	0	2	0	0	0
Prostate	(49)	(46)	(47)	(48)	(49)	(46)	(47)	(48)
Atrophy	48	38	44	43	48	38	44	43
Inflammation	4	14	8	12	4	14	8	12
Epididymis	(49)	(47)	(50)	(50)	(49)	(47)	(50)	(50)
Atrophy	48	45	48	48	48	45	48	48
Seminal vesicle	(50)	(48)	(47)	(49)	(50)	(48)	(47)	(49)
Atrophy	44	42	44	44	44	42	44	41

\*\*Statistically significant over controls p<0.01



---

Page \_\_\_\_\_ is not included in this copy.

Pages 8 through 9 are not included in this copy.

---

The material not included contains the following type of information:

\_\_\_\_\_ Identity of product inert ingredients.

\_\_\_\_\_ Identity of product impurities.

\_\_\_\_\_ Description of the product manufacturing process.

\_\_\_\_\_ Description of quality control procedures.

\_\_\_\_\_ Identity of the source of product ingredients.

\_\_\_\_\_ Sales or other commercial/financial information.

\_\_\_\_\_ A draft product label.

\_\_\_\_\_ The product confidential statement of formula.

\_\_\_\_\_ Information about a pending registration action.

\_\_\_\_\_ FIFRA registration data.

\_\_\_\_\_ The document is a duplicate of page(s) \_\_\_\_\_.

\_\_\_\_\_ The document is not responsive to the request.

---

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

---